{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:50:36Z","timestamp":1789429836347,"version":"build-2803163510"},"reference-count":50,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Braeburn Pharmaceuticals"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,8,3]]},"DOI":"10.1080\/17512433.2017.1336434","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T08:03:02Z","timestamp":1496390582000},"page":"799-807","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Buprenorphine implants in medical treatment of opioid addiction"],"prefix":"10.1080","volume":"10","author":[{"given":"Steven","family":"Chavoustie","sequence":"first","affiliation":[{"name":"Women\u2019s Health, Segal Institute for Clinical Research, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Frost","sequence":"additional","affiliation":[{"name":"The Frost Medical Group, Conshohocken, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Snyder","sequence":"additional","affiliation":[{"name":"Scripps Coastal Medical Center, Vista, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Owen","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Union University, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Darwish","sequence":"additional","affiliation":[{"name":"Sci-Med Bridge, Malvern, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Dammerman","sequence":"additional","affiliation":[{"name":"Medical Affairs, Braeburn Pharmaceuticals, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Sanjurjo","sequence":"additional","affiliation":[{"name":"Medical Affairs, Braeburn Pharmaceuticals, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,6,21]]},"reference":[{"key":"CIT0001","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000."},{"key":"CIT0003","unstructured":"Center for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, Mortality File. Number and Age-Adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000\u20132014. Atlanta (GA): Center for Disease Control and Prevention; 2015. Available from: http:\/\/www.cdc.gov\/nchs\/data\/health_policy\/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf"},{"issue":"16","key":"CIT0004","first-page":"443","volume":"64","author":"Conrad C","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu643"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000075"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022164"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.574"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.121"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9345157.x"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.00287.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5416"},{"key":"CIT0015","first-page":"CD002207","volume":"2","author":"Mattick RP","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2010.531672"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05356-2"},{"key":"CIT0018","first-page":"CD002207","volume":"3","author":"Mattick RP","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0019","unstructured":"Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2004. (Treatment Improvement Protocal (TIP) Series 40; DHHS Publication No. SMA 04-3939). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64245\/pdf\/Bookshelf_NBK64245.pdf"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300256"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2007.03.002"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711104010028"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000045"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.12.005"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.02.003"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdv150"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1159\/000438988"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2008.07.015"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2009.00002.x"},{"issue":"3","key":"CIT0030","first-page":"56","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"CIT0031","first-page":"CD000011","volume":"11","author":"Nieuwlaat R","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2011.00186.x"},{"key":"CIT0033","unstructured":"PROBUPHINE\u00ae (buprenorphine) implant for subdermal administration. Full prescribing information. Princeton (NJ): Braeburn Pharmaceuticals; 2016."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1126\/science.7352279"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480200058024"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00061-9"},{"key":"CIT0037","first-page":"CD011117","volume":"5","author":"Nielsen S","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"CIT0040","unstructured":"Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2005. (Treatment Improvement Protocal (TIP) Series 43; HHS Publication No. SMA 12-4214). Available from: http:\/\/store.samhsa.gov\/shin\/content\/\/SMA12-4214\/SMA12-4214.pdf"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000052"},{"key":"CIT0042","unstructured":"SUBOXONE\u00ae (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets) and SUBUTEX\u00ae (buprenorphine HCl sublingual tablets). Full prescribing information. Richmond (VA): Reckitt Benckiser Pharmaceuticals; 2013."},{"key":"CIT0043","unstructured":"SUBOXONE\u00ae (buprenorphne and naloxone) sublingual film for sublingual or buccal use. Full prescribing information. Richmond (VA): Indivior; 2015."},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1021\/jm960073m"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.11.014"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2011.01134.x"},{"issue":"2","key":"CIT0047","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","volume":"297","author":"Huang P","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9382"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1427"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1111\/add.12315"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.4172\/2324-9005.1000162"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2017.1336434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:49:03Z","timestamp":1750286943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2017.1336434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,21]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,7,3]]},"published-print":{"date-parts":[[2017,8,3]]}},"alternative-id":["10.1080\/17512433.2017.1336434"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2017.1336434","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}